Skip to main content
Clinical Trials/NCT00662727
NCT00662727
Completed
Phase 2

Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device

Medispec1 site in 1 country28 target enrollmentJanuary 2007

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Refractory Angina Pectoris
Sponsor
Medispec
Enrollment
28
Locations
1
Primary Endpoint
Total Exercise Time
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

Detailed Description

Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to myocardial ischemic tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave to avoid arrhythmias. The treatment is painless. At first, the patient undergoes stress- SPECT testing to identify the ischemic areas. Following that, the same area is localized by the ultra-sound device and the shockwaves are focused to the ischemic area. Several treatments are required for optimal results.

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
November 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Medispec
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with chronic stable angina pectoris.
  • Documented myocardial segments with reversible ischemia
  • AP CCS class of III-IV.
  • Stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.
  • Exercise tolerance time \< 10 min (modified Bruce)
  • Two ETT tests results (within two weeks) averaging no more than 25% of their mean
  • Documented epicardial coronary artery disease not amenable to angioplasty or CABG.
  • Signed an IRB approved informed consent form.
  • Life expectancy of \>12 months.

Exclusion Criteria

  • Intraventricular thrombus
  • Malignancy in the area of treatment
  • Severe COPD
  • No smoking during the study procedure
  • MI less \<3 months prior to treatment
  • Severe Valvular disease
  • Child bearing potential

Outcomes

Primary Outcomes

Total Exercise Time

Time Frame: 6 months

Secondary Outcomes

  • Change in SPECT(6 months)
  • Change in AP-CCS(6 months)

Study Sites (1)

Loading locations...

Similar Trials